Pearl Therapeutics

Pearl was founded in 2006, with a mission and vision to develop differentiated therapeutics for widely prevalent respiratory disease conditions, including chronic obstructive pulmonary disease (COPD), by utilising a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers (MDIs).

 

In 2007, Pearl began the development of leading product candidates with initial venture funding from 5AM Ventures, Clarus Ventures and New Leaf Ventures. In 2010, Vatera Healthcare Partners joined Pearl as a fourth investor. Between 2007-2013, Pearl’s four investors backed it with $167.5 million, allowing the progression of key therapeutic areas.

Subsequently, in 2013, AstraZeneca acquired Pearl to expand and strengthen its respiratory products portfolio and have made strides in bringing therapies to asthma patients.

Notably, Pearl’s lead combination medicine was recently launched in the US during the first quarter of 2017 and has regulatory submission acceptance in EU for COPD. Thanks to the Pearl team’s experience as inhalation product development experts, another lead product candidate is progressing through the pipeline as a potential treatment for COPD and asthma.


Pearl successfully delivered valuable therapeutics for a range of respiratory patients. As part of the AstraZeneca Group, we will continue the ongoing commitment to progress developments and innovation in respiratory science.

Colin Reisner CEO of Pearl Therapeutics and Head of Respiratory Global Medicines

Our Respiratory pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.


Respiratory (as at 9 November 2017)

Phase 1

Phase 1

  • AZD0284 psoriasis/respiratory
  • AZD5634 cystic fibrosis
  • AZD7594 + abediterol asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • AZD9898 asthma
  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • AZD1419 asthma
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • PT010 asthma
  • abediterol asthma/chronic obstructive pulmonary disease
  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere PINNACLE chronic obstructive pulmonary disease
  • PT010 chronic obstructive pulmonary disease
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

A Career at Pearl